Skip to main content
SpringerLink
Log in

Topical Corticosteroids and the Risk of Diabetes Mellitus

A Nested Case-Control Study in the Netherlands

  • Original Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background: The relationship between topical corticosteroid use, potency, treatment duration, concomitant exposure to systemic corticosteroids, and risk of diabetes has been incompletely studied.

Objective: To investigate an association between intense, longstanding topical corticosteroid use and diabetes mellitus.

Methods: Data for this nested case-control study were obtained from the PHARMO Record Linkage System, including linked drug dispensing and hospital records of >2.5 million individuals in defined areas of the Netherlands. Users of topical corticosteroids during 1992–2004, without diabetes, with ≥2 topical corticosteroid dispensings and ≥4 years of follow-up were selected. Diabetes onset was defined as first occurrence (index date) of an antidiabetic drug dispensing or hospitalization for diabetes. Cases were matched 1:4 by age and sex to controls, with ≥2 topical corticosteroid dispensings and similar follow-up duration. Use of topical corticosteroids and systemic corticosteroids and/or inhaled corticosteroids as co-medication was classified as current, recent and past/never (≤2 years, 2–4 years and >4 years ago, respectively). Multivariate regression analyses were adjusted for co-medication and co-morbidity.

Results: Among 192 893 incident topical corticosteroid users, 2212 developed diabetes and could be matched to 8582 controls. Current topical corticosteroid use was associated with an (unadjusted) 1.24-fold increased risk of diabetes (unadjusted OR 1.24; 95% CI 1.11, 1.40). The odds ratio increased to 1.32 with >180 days of topical corticosteroid use (95% CI 1.14, 1.54) and to 1.44 with a cumulative topical corticosteroid load (combined potency and amount) of 731–1460 mg (95% CI 1.21, 1.72). Among past/never users of systemic corticosteroids and/or inhaled corticosteroids, current use of topical corticosteroids remained associated with a 1.27-fold increased diabetes risk (unadjusted OR 1.27; 95% CI 1.10, 1.47) compared with past users of topical corticosteroids.

Conclusion: An increased risk of new-onset diabetes may be an important consideration in the treatment of patients with topical corticosteroids, especially when intense skin treatment is needed. Future studies are needed to endorse these findings in other populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Carruthers JA, August PJ, Staughton RC. Observations on the systemic effect of topical clobetasol propionate (Dermovate). Br Med J 1975; 4(5990): 203–4

    Article  PubMed  CAS  Google Scholar 

  2. Nilsson JE, Gip LJ. Systemic effects of local treatment with high doses of potent corticosteroids in psoriatics. Acta Derm Venereol 1979; 59(3): 245–8

    PubMed  CAS  Google Scholar 

  3. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 2002; 3(3): 141–7

    Article  PubMed  Google Scholar 

  4. Abma EM, Blanken R, De Heide LJ. Cushing’s syndrome caused by topical steroid therapy for psoriasis. Neth J Med 2002; 60(3): 148–50

    PubMed  CAS  Google Scholar 

  5. Gilbertson EO, Spellman MC, Piacquadio DJ, et al. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol 1998; 38 (2 Pt 2): 318–21

    Article  PubMed  CAS  Google Scholar 

  6. Weber SL. Cushing’s syndrome attributable to topical use of lotrisone. Endocr Pract 1997; 3(3): 140–4

    PubMed  CAS  Google Scholar 

  7. Reynolds RM, Syddall HE, Walker BR, et al. Predicting cardiovascular risk factors from plasma cortisol measured during oral glucose tolerance tests. Metabolism 2003; 52(5): 524–7

    Article  PubMed  CAS  Google Scholar 

  8. Poa NR, Edgar PF. Insulin resistance is associated with hypercortisolemia in Polynesian patients treated with antipsychotic medication. Diabetes Care 2007; 30(6): 1425–9

    Article  PubMed  CAS  Google Scholar 

  9. Sasaki N, Iwase M, Arima H, et al. Overt diabetes mellitus in a patient with combined primary aldosteronism and Cushing’s syndrome. Intern Med 2006; 45(21): 1237–42

    Article  PubMed  Google Scholar 

  10. Aalto-Korte K, Turpeinen M. Quantifying systemic absorption of topical hydrocortisone in erythroderma. Br J Dermatol 1995; 133(3): 403–8

    Article  PubMed  CAS  Google Scholar 

  11. Dekhuijzen PN, Honour JW. Inhaled corticosteroids and the hypothalamic-pituitary-adrenal (HPA) axis: do we understand their interaction? Respir Med 2000; 94(7): 627–31

    Article  PubMed  CAS  Google Scholar 

  12. Barnes N. The properties of inhaled corticosteroids: similarities and differences. Prim Care Resp J 2007; 16(3): 149–54

    Article  Google Scholar 

  13. Dendukuri N, Blais L, LeLorier J. Inhaled corticosteroids and the risk of diabetes among the elderly. Br J Clin Pharmacol 2002; 54(1): 59–64

    Article  PubMed  CAS  Google Scholar 

  14. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002; 17(9): 717–20

    Article  PubMed  Google Scholar 

  15. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006; 29(12): 2728–9

    Article  PubMed  CAS  Google Scholar 

  16. Gomez EC, Frost P. Induction of glycosuria and hyperglycemia by topical corticosteroid therapy. Arch Dermatol 1976; 112(11): 1559–62

    Article  PubMed  CAS  Google Scholar 

  17. Sobngwi E, Lubin V, Ury P, et al. Adrenal insufficiency and diabetes mellitus secondary to the use of topical corticosteroids for cosmetic purpose. Ann Endocrinol (Paris) 2003; 64(3): 202–4

    CAS  Google Scholar 

  18. Delea TE, Gokhale M, Makin C, et al. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pime-crolimus or tacrolimus. J Manag Care Pharm 2007; 13(4): 349–59

    PubMed  Google Scholar 

  19. CDC National Center for Health Statistics. International classification of diseases. 9th rev., clinical modification (ICD-9-CM) [online]. Available from URL: http://www.cdc.gov/nchs/about/otheract/icd9/abticd9.htm [Accessed 2009 Mar 31]

  20. Herings RM. PHARMO: a record linkage system for post-marketing surveillance of prescription drugs in The Netherlands [dissertation]. Utrecht: Utrecht University, Department of Pharmaco-epidemiology and Pharmaco-therapy, 1993

    Google Scholar 

  21. Hodari KT, Nanton JR, Carroll CL, et al. Adherence in dermatology: a review of the last 20 years. J Dermatolog Treat 2006; 17(3): 136–42

    Article  PubMed  Google Scholar 

  22. Herings RMC, de Jong R, on behalf of the PHARMO Institute for Drug Outcomes Research. Market exploration report: topical corticosteroids [in Dutch]. Utrecht: PHARMO Institute for Drug Outcomes Research, 2004

    Google Scholar 

  23. Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003; 148(1): 128–33

    Article  PubMed  CAS  Google Scholar 

  24. Koro CE, Fedder DO, L’Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325(7358): 243

    Article  PubMed  CAS  Google Scholar 

  25. Citrome LL, Jaffe AB. Relationship of atypical anti-psychotics with development of diabetes mellitus. Ann Pharmacother 2003; 37(12): 1849–57

    Article  PubMed  Google Scholar 

  26. Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007; 57(1): 81–3

    Article  PubMed  Google Scholar 

  27. Vlaski E, Stavric K, Isjanovska R, et al. Overweight hypothesis in asthma and eczema in young adolescents. Allergol Immunopathol (Madr) 2006; 34(5): 199–205

    Article  CAS  Google Scholar 

  28. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med 2007; 167(15): 1670–5

    Article  PubMed  Google Scholar 

  29. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157(6): 1249–51

    Article  PubMed  CAS  Google Scholar 

  30. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149(11): 981–3

    Article  PubMed  CAS  Google Scholar 

  31. Atherton DJ. Topical corticosteroids in atopic dermatitis. BMJ 2003; 327(7421): 942–3

    Article  PubMed  Google Scholar 

  32. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4(37): 1–191

    PubMed  CAS  Google Scholar 

  33. Callen J, Chamlin S, Eichenfield LF. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2006; 152(2): 1–19

    Google Scholar 

  34. Bruner CR, Feldman SR, Ventrapragada M, et al. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003; 9(1): 2

    PubMed  Google Scholar 

  35. Van Der Meer JB, Glazenburg EJ, Mulder PG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999; 140(6): 1114–21

    Google Scholar 

  36. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326(7403): 1367

    Article  PubMed  CAS  Google Scholar 

  37. Boukes FS, Wiersma T, Cleveringa JP, et al. Summary of the practice guideline ‘atopic dermatitis’ (first revision) from the Dutch College of General Practitioners. Ned Tijdschr Geneeskd 2007; 151(25): 1394–8

    PubMed  CAS  Google Scholar 

  38. Bruijnzeel-Koomen CA, Sillevis Smitt JH, Boukes FS, et al. The practice guideline ‘atopic dermatitis’. Ned Tijdschr Geneeskd 2007; 151(25): 1399–402

    PubMed  CAS  Google Scholar 

  39. Charman CR, Morris AD, Williams HC. Topical cortico-steroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142(5): 931–6

    Article  PubMed  CAS  Google Scholar 

  40. Charman C, Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 2003; 21(3): 193–200

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work has been presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual European Congress 2007. J.W. Kerkvliet is kindly acknowledged for writing support. V. Thomas is acknowledged for comments. ## This work was financially supported by Novartis Pharma, Horsham, UK. The authors confirm that the paper is an accurate representation of the study results. Role of the funding source: in study design —none; in collection, analysis and interpretation of the data —none; in writing of this report —none; in the decision to submit the paper for publication —none. ## Michiel van der Linden, Fernie Penning-van Beest and Ron Herings are employees of the PHARMO Institute, which performs financially supported studies for several pharmaceutical companies. Tamar Nijsten has no conflicts of interest to declare that are directly relevant to this study.

Author information

Authors and Affiliations

  1. PHARMO Institute for Drug Outcome Research, P.O. Box 85222, 3508 AE, Utrecht, the Netherlands

    Michiel W. van der Linden,  Fernie J. A. Penning-van Beest & Ron M. C. Herings

  2. Department of Dermatology, Erasmus Medical Centre, Rotterdam, the Netherlands

    Tamar Nijsten

  3. Department of Health Policy & Management, Erasmus Medical Centre, Rotterdam, the Netherlands

    Ron M. C. Herings

Authors
  1. Michiel W. van der Linden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fernie J. A. Penning-van Beest
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tamar Nijsten
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ron M. C. Herings
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernie J. A. Penning-van Beest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Linden, M.W., Beest, F.J.A.Pv., Nijsten, T. et al. Topical Corticosteroids and the Risk of Diabetes Mellitus. Drug-Safety 32, 527–537 (2009). https://doi.org/10.2165/00002018-200932060-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200932060-00008

Keywords

Search

Navigation